it is an HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) intended to be administered in combination with other antiretroviral medicines. it is available by itself or as a combination product of it (100 mg), lamivudine (300 mg), and tenofovir disoproxil fumarate (300 mg).  it is formally indicated for the treatment of HIV-1 infection in adult patients with no prior antiretroviral treatment experience, further expanding the possibility and choice of therapeutic treatments available for the management of HIV-1 infection. 
